

Macular Degeneration Age-Related Macular Degeneration

## Study of Zifibancimig in Participants With Neovascular Age-related Macular Degeneration

**Trial Status**  
Active, not recruiting

**Trial Runs In**  
2 Countries

**Trial Identifier**  
NCT04567303 BP41670

---

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

### ***Trial Summary:***

This is a first in-human study to investigate the safety, tolerability and efficacy of zifibancimig administered through intravitreal (IVT) injections and via the port delivery (PD) implant in participants with neovascular age-related macular degeneration (nAMD).

**Hoffmann-La Roche**  
Sponsor

**Phase 1/Phase 2**  
Phase

---

**NCT04567303 BP41670**  
Trial Identifiers

---

### ***Eligibility Criteria:***

**Gender**  
All

**Age**  
≥50 Years

**Healthy Volunteers**  
No

---